Showing 1241-1250 of 1635 results for "".
- Bausch + Lomb Launches Dry Eye Education Campaignhttps://modernod.com/news/bausch-lomb-launches-dry-eye-education-campaign/2482872/Bausch + Lomb announced the launch of “Eyes Tell the Story: The Impact of Dry Eye,” a new awareness campaign designed to spotlight the burden of dry eye symptoms through storytelling, photography, and insights from the company’s latest nationw
- Ocumetics Initiates First-In-Human Study of Accommodating Intraocular Lenshttps://modernod.com/news/ocumetics-initiates-first-in-human-study-of-accommodating-intraocular-lens/2482866/Ocumetics Technology has initiated the first-in-human (FIH) clinical studies for its accommodating intraocular lens, known as the Ocumetics Lens. Designed to mimic the natural focusing ability of the youthful hu
- Heidelberg Engineering Launches ZinserLab Innovation Hub to Accelerate Imaging Innovation in Eye Carehttps://modernod.com/news/heidelberg-engineering-launches-zinserlab-innovation-hub-to-accelerate-imaging-innovation-in-eye-care/2482848/Heidelberg Engineering announced the launch of the ZinserLab, an innovation hub that aims to accelerate the development of imaging technologies with clinical value for eye care. The hub is named in honor of Dr. Gerhard Zinser, the
- EMA Review Finds Rare Risk of Vision Loss Associated With Semaglutide Medicineshttps://modernod.com/news/ema-review-finds-rare-risk-of-vision-loss-associated-with-semaglutide-medicines/2482842/The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines following concerns about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAIO
- Zeiss Clarus 700 Receives NMPA Approval in Chinahttps://modernod.com/news/zeiss-clarus-700-receives-nmpa-approval-in-china/2482840/Zeiss Medical Technology announced that the Clarus 700 has received National Medical Products Administration (NMPA) approval in China. According to Zeiss, the Clarus 700 offers advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in true c
- NIH Researchers Identify Brain Circuits Responsible for Visual Acuityhttps://modernod.com/news/nih-researchers-identify-brain-circuits-responsible-for-visual-acuity/2482836/Researchers at the National Institutes of Health (NIH) says they have identified specific brain circuits vital to visual acuity and uncovered how these circuits are disrupted by damage to retinal cells, a discovery that could reshape the future of vision resto
- CIRM Awards $4.7 Million for Vision Loss Gene Therapyhttps://modernod.com/news/cirm-awards-47-million-for-vision-loss-gene-therapy/2482827/The California Institute for Regenerative Medicine (CIRM) awarded $4.7 million to Blue Gen Therapeutics Foundation (Principal Investigator Aaron Nagiel, MD, PhD) to fund preclinical research that aims to develop a gene therapy for the rare disease blue cone monochromacy (BCM). <
- Eylea 8 mg Approved in China for Wet AMDhttps://modernod.com/news/eylea-8-mg-approved-in-china-for-wet-amd/2482817/The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Eylea 8 mg (aflibercept 8 mg) for the treatment of wet age-related macular degeneration (AMD) in China. The approval is based on positive results from the phase 3 PULSAR trial a
- NIH Study: Experimental Drug May Help Treat Condition May Help Treat Diabetic Retinopathyhttps://modernod.com/news/nih-study-experimental-drug-may-help-treat-condition-may-help-treat-diabetic-retinopathy/2482805/A new National Institutes of Health (NIH)-funded study led by scientists at the Wilmer Eye Institute, Johns Hopkins Medicine researchers determined that low blood sugar, or hypoglycemia, may promote a breakdown of the blood-retinal barrier, an important boundary that regulates the flow of nu
- Ashvattha Therapeutics Presents Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Diseasehttps://modernod.com/news/ashvattha-therapeutics-present-positive-phase-2-results-for-subcutaneous-migaldendranib-in-retinal-vascular-disease-at-arvo/2482795/Ashvattha Therapeutics announced positive interim phase 2 results for migaldendranib (MGB), a novel subcutaneously administered nanomedicine treatment for retinal vascular diseases. Updated results were presented in a poster session at the